Since launching commercial sales in 2018, Ceribell has expanded rapidly with its AI-enabled rapid EEG system in acute care settings, backed by FDA clearances and patents. Despite robust top-line growth trends implied by increased headcount and investments, the company remains unprofitable with widening operating losses and negative cash flow in latest fiscal years. Key growth drivers include expanding hospital adoption and subscription revenues for its wearable EEG headbands combined with cloud analytic platform. Yet, significant challenges loom from manufacturing scale-up, ongoing patent litigations, reimbursement uncertainties, regulatory compliance complexities, and entrenched competition from legacy EEG providers. Monitoring quarterly financials for inflection towards operating leverage and progress on patent litigation outcomes will be essential to assess long-term viability.